Biotechnology Business Investment Opportunities in Brussels

An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.

An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.